FY2025 · ended Dec 31, 2025 · Revenue $1.93M, -79.2% YoY · Filed Apr 1, 2026
iSpecimen Inc. (ISPC) files with the SEC under industry code 8731, Services-Commercial Physical & Biological Research. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $1.9 million and a net loss of $10.5 million. Free cash flow was -$4.2 million. As of Jun 30, 2026 it held $4.4 million in cash and investments and $240,903 in total debt.
Revenue (TTM)
$466,302
-92.1% vs year-ago TTM
Net income (TTM)
$-11.42M
-12.0% vs year-ago TTM
Operating cash flow (TTM)
$-7.00M
-17.9% vs year-ago TTM
Free cash flow
$-4.24M
+48.9% vs prior year
EPS (TTM)
$-2.28
+89.1% vs year-ago TTM
Dividend per share
None
Shares outstanding
29.66M
+1088.0% vs prior year
Net cash
$4.17M
as of Jun 30, 2026
Operating margin
-2020.0%
FY 2026
Company profile
- Industry
- Services-Commercial Physical & Biological Research (SIC 8731)
- Listed as
- ISPC (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Woburn, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1558569
Other Services-Commercial Physical & Biological Research companies
- Iqvia Holdings Inc. IQV
- Incyte Corp INCY
- Medpace Holdings, Inc. MEDP
- Charles River Laboratories International, Inc. CRL
- Icon PLC ICLR
- Absci Corp ABSI
- OmniAb, Inc. OABI
- NRC Health NRC
All 17 Services-Commercial Physical & Biological Research companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $1.9M | $9.3M | $9.9M | $10.4M | $11.1M |
| Operating income | -$9.0M | -$12.7M | -$11.2M | -$10.2M | -$5.9M |
| Net income | -$10.5M | -$12.5M | -$11.1M | -$10.2M | -$9.0M |
| Diluted EPS | -$2.28 | -$17.58 | -$24.55 | -$1.16 | -$2.09 |
| Operating cash flow | -$4.2M | -$8.3M | -$5.8M | -$5.8M | -$10.7M |
| Free cash flow | -$4.2M | -$8.3M | -$5.8M | -$6.0M | -$10.7M |
| Total assets | $9.5M | $9.4M | $15.8M | $24.6M | $35.7M |
| Total liabilities | $6.4M | $6.0M | $6.1M | $4.3M | $5.9M |
| Stockholders' equity | $3.1M | $3.3M | $9.7M | $20.3M | $29.8M |
| Cash and investments | $6.9M | $1.9M | $5.0M | $15.3M | $27.7M |
| Total debt | $268,798 | $312,167 | $196,244 | $185,847 | $3.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Unregistered share sale, Change in control, Regulation FD disclosure
|
Nov 5, 2026 | Nov 2, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Nov 2, 2026 | Oct 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Oct 9, 2026 | Oct 9, 2026 |
| 8-K |
Current report
Listing notice
|
Sep 10, 2026 | Sep 8, 2026 |
| 8-K |
Current report
Material agreement
|
Sep 4, 2026 | Sep 4, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 31, 2026 | Aug 26, 2026 |
All 333 iSpecimen Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.